Clinical Trials List
2025-10-31 - 2029-02-04
Phase III
Not yet recruiting1
Recruiting5
ICD-10C79.81
Secondary malignant neoplasm of breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9198.81
Secondary malignant neoplasm of breast
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/06/01
Investigators and Locations
Co-Principal Investigator
- 林季宏 Division of Hematology & Oncology
- 郭文宏 Division of General Surgery
- 李怡範 Division of Radiology
- MING-YANG WANG Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
- YEN-SHEN LU Division of Hematology & Oncology
- 陳怡君 Division of Hematology & Oncology
- 黃柏翔 Division of Hematology & Oncology
- 陳怡君 Division of Hematology & Oncology
- 張端瑩 Division of Hematology & Oncology
- 楊明翰 Division of Hematology & Oncology
- 羅喬 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 周旭桓
- Mengting Peng Division of Hematology & Oncology
- Wen-Chi Shen
- Chan-Keng Yang Division of Hematology & Oncology
- 沈士哲
- Yung-Chang Lin Division of Hematology & Oncology
- Chi-Chang Yu
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林燕淑
- 馮晉榮 Division of General Surgery
- Yi-Fang Tsai Division of General Surgery
- Chi-Cheng Huang
- 鄭涵方 Division of General Surgery
- Chun-Yu Liu
- Jiun-I Lai Division of Hematology & Oncology
- Ta-Chung Chao Division of Hematology & Oncology
- 賴亦貞 Division of Radiology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
42 participants
-
Global
400 participants
